Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
121. |
ECCT/24/03/06 | PHOENIx MDR-TB) Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) |
Principal Investigator(s) 1. Dr Lucy Chepkurui Koech KOECH Site(s) in Kenya 1. Kenya medical Research Institute/ Walter Reed Project (Kericho county) 2. Moi university clinic research Centre (Uasin Gishu county) |
21-05-2024 |
View |
122. |
ECCT/24/03/04 | MK8591A-053 Trial A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Nelly Rwamba Mugo Site(s) in Kenya 1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county) 2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county) 3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county) |
19-06-2024 |
View |
123. |
ECCT/24/03/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr. Janet Nyawira Oyieko Site(s) in Kenya 1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) |
14-05-2024 |
View |
124. |
ECCT/24/03/03 | DoxyDOT Study Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI CMR RCTP |
31-05-2024 |
View |
125. |
ECCT/24/03/01 | RAD-TB A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis |
Principal Investigator(s) 1. Dr Josphat Kosgei Kosgei Site(s) in Kenya Kenya medical research institute/ Walter Reed program KERICHO |
26-11-2024 |
View |
126. |
ECCT/24/02/08 | H06_02TP A Phase 2 single-blind, randomized, controlled, single center study to assess the immunogenicity and safety of a 2-dose schedule with GVGH altSonflex1-2-3 vaccine in African infants (H06_02TP) |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WRP CRC KERICHO |
31-05-2024 |
View |
127. |
ECCT/24/02/07 | CO-SAM An adaptive multi-arm trial to improve clinical outcomes among children recovering from complicated severe acute malnutrition (CO-SAM) |
Principal Investigator(s) 1. Benson Singa Site(s) in Kenya 1. Homabay County Referral hospital (Homa Bay county) 2. Migori County Referral Hospital (Migori county) 3. Mbagathi County Referral Hospital (Nairobi City county) 4. Coast General Teaching and Referral Hospital (Mombasa county) |
03-12-2024 |
View |
128. |
ECCT/24/04/04 | TNBC A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya 1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county) 2. International Cancer Institute (Nandi county) 3. The Aga Khan University Hospital - Kenya (Nairobi City county) |
19-09-2024 |
View |
129. |
ECCT/24/02/10 | IMBrave A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Principal Investigator(s) 1. Dr. Pauline Njoki Njiraini Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
09-06-2024 |
View |
130. |
ECCT/24/02/04 | IGHID 12333 IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya. |
Principal Investigator(s) 1. Chemtai Mungo Site(s) in Kenya Lumumba subcounty Hospital Kisumu |
26-04-2024 |
View |